BEQALZI(Sonrotoclax)

Inquire / Price
  • Model Number:
    RL772026051501
  • Brand Name:
    BEQALZ™I (百悦达®)
  • Origin:
    Original invention from China
  • Small Orders:
    Small batches also available
  • Tags:
Inquire Now Link

Poster
  • Details
  • Description
  • Packaging Size
    120t/Bottle
  • Strength
    80mg
  • Compositon
    Sonrotoclax
  • Treatment
    Mantle cell lymphoma
  • Form
    Tablet
  • Brand
    BEQALZ™I (百悦达®)
  • Quantity Unit
    80mg*120t/Box
  • Manufacturer
    BeOne Medicines Ltd.,China

About Sonrotoclax

Sonrotoclax is a potent and selective BCL2 inhibitor that can overcome resistance associated with BCL2 mutations, such as the G101V variant, which limits the effectiveness of first-generation inhibitors like venetoclax.

The FDA has granted accelerated approval to sonrotoclax (Beqalzi) for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least 2 lines of systemic therapy, including a BTK inhibitor.

Doseage

Sonrotoclax dosing is recommended to begin with a 4-week ramp-up phase to reduce the risk of TLS, followed by 320 mg once per day until disease progression or unacceptable toxicity.

Dosage specifications

  • 1mg*11t/Box
  • 5mg*11t/Box
  • 20mg*11t/Box
  • 80mg*120t/Box

 


Link

Poster

Top